AXGN
Axogen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$44.23
−2.33%Year over year
Reported trailing growth
- Revenue
- +23.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -40.7%
- Operating cash flow
- +29.7%
Forward estimates
Based on analyst estimates
- Revenue
- +21.1%
- EBITDA
- +467.8%
- EPS
- +185.9%
Three-year CAGR
- Revenue
- +17.6%
- EBITDA
- -96.8%
- EBIT
- —
- Net income
- -57.6%
- EPS
- -47.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026